2024 ´ëÇÑÄ¡¸ÅÇÐȸ Ãá°è Çмú´ëȸ : 2024-04-20 |
|
2024 ´ëÇÑÄ¡¸ÅÇÐȸ Ãá°è Çмú´ëȸ : 2024-04-20 ±³À°ÁÖÁ¦ : 2024 ´ëÇÑÄ¡¸ÅÇÐȸ Ãá°è Çмú´ëȸ ÁÖÃÖ±â°ü : ´ëÇÑÄ¡¸ÅÇÐȸ À̸ÞÀÏ : secretkda@thedementia.co.kr ±³À°Á¾·ù : ½Å°æ°ú Âü¼®¿¹»óÀÎ : 300¸í Áö¿ª : ¼¿ïƯº°½Ã ¼¼ºÎ¼ö°·á : 120,000¿ø ºñ°í »çÀüµî·Ï: ÀϹÝȸ¿ø 4¸¸¿ø, Á¤È¸¿ø 6¸¸¿ø, ºñȸ¿ø 11¸¸¿ø / ´çÀϵî·Ï: ÀϹÝȸ¿ø 5¸¸¿ø, Á¤È¸¿ø 7¸¸¿ø, ºñȸ¿ø 12¸¸¿ø
±âŸ 04¿ù 20ÀÏ ¹é¹ü±è±¸±â³ä°ü 08:50~09:00 Opening Remarks À±¿µÃ¶(´ëÇÑÄ¡¸ÅÇÐȸÀå) ±³À°½Ã°£ 04¿ù 20ÀÏ ¹é¹ü±è±¸±â³ä°ü (Room A) 09:00~09:20 Elecsys AD CSF biomarker best practice sharing of other countries Cristiano Tunesi(Roche Diagnostics International) ±³À°½Ã°£ 04¿ù 20ÀÏ ¹é¹ü±è±¸±â³ä°ü (Room A) 09:20~09:40 Lecanemab in Early Alzheimer¡¯s Disease: Tau PET, Long-Term Outcomes, and Subcutaneous Formulation Michael Irizarry(Eisai) ±³À°½Ã°£ 04¿ù 20ÀÏ ¹é¹ü±è±¸±â³ä°ü (Room A) 09:40~10:00 Baseline Characteristics Associated with Achieving Rapid Amyloid Plaque Clearance Following Donanemab Treatment Saygin Gonderten(Lilly) ÈÞ½Ä 04¿ù 20ÀÏ ¹é¹ü±è±¸±â³ä°ü 10:00~10:20 Coffee Break () ±³À°½Ã°£ 04¿ù 20ÀÏ ¹é¹ü±è±¸±â³ä°ü (Room A) 10:20~11:10 Monoclonal antibodies: how to apply the new hope in clinics ¾çµ¿¿ø(°¡Å縯ÀÇ´ë) ±³À°½Ã°£ 04¿ù 20ÀÏ ¹é¹ü±è±¸±â³ä°ü (Room A) 11:10~12:00 Insights into mechanisms of ARIA from preclinical models - 20 years of research Donna M. Wilcock(Indiana University) ±âŸ 04¿ù 20ÀÏ ¹é¹ü±è±¸±â³ä°ü (Room A) 12:00~13:00 ÃÑȸ () Åä·Ð 04¿ù 20ÀÏ ¹é¹ü±è±¸±â³ä°ü 13:00~14:00 Poster Presentation () ±³À°½Ã°£ 04¿ù 20ÀÏ ¹é¹ü±è±¸±â³ä°ü (Room A) 14:00~14:12 [±¸¿¬] Enhancement of glymphatic activity in early Alzheimer¡¯s disease using low-intensity ultrasound treatment ±èÀçÈ£(ÇѸ²´ëÇб³µ¿Åº¼º½Éº´¿ø) ±³À°½Ã°£ 04¿ù 20ÀÏ ¹é¹ü±è±¸±â³ä°ü (Room A) 14:12~14:24 [±¸¿¬] Evaluation of Efficacy and Safety of Low Dose Ionizing Radiation Therapy on Alzheimer¡¯s Disease: Interim Results of Multicenter Randomized, Single Blind, Phase II Clinical Trial Á¤¿ø±Ô(°µ¿°æÈñ´ëÇб³º´¿ø) ±³À°½Ã°£ 04¿ù 20ÀÏ ¹é¹ü±è±¸±â³ä°ü (Room A) 14:24~14:36 [±¸¿¬] Effectiveness of personalized hippocampal network-targeted stimulation in Alzheimer¡¯s disease: A randomized controlled trial Á¤¿µÈñ(¸íÁöº´¿ø) ±³À°½Ã°£ 04¿ù 20ÀÏ ¹é¹ü±è±¸±â³ä°ü (Room A) 14:36~14:48 [±¸¿¬] The Efficacy of a Home-Based, Augmented Reality Dual-Task Platform for Cognitive-Motor Training in Elderly Patients: A Pilot Observational Study À±º¸¶ó(°¡Å縯´ëÇб³ ¼¿ï¼º¸ðº´¿ø) ±³À°½Ã°£ 04¿ù 20ÀÏ ¹é¹ü±è±¸±â³ä°ü (Room A) 14:48~15:00 [±¸¿¬] Presence of gait improvement 1 month after the CSF tap test in idiopathic normal pressure hydrocephalus ±è¹ÎÁÖ(ºÐ´ç¼¿ï´ëÇб³º´¿ø) ÈÞ½Ä 04¿ù 20ÀÏ ¹é¹ü±è±¸±â³ä°ü (Room A) 15:00~15:10 Coffee Break () ±³À°½Ã°£ 04¿ù 20ÀÏ ¹é¹ü±è±¸±â³ä°ü (Room A) 15:10~15:30 Treatment-tailored cognitive change detection À̺´È(»ï¼º¼¿ïº´¿ø) ±³À°½Ã°£ 04¿ù 20ÀÏ ¹é¹ü±è±¸±â³ä°ü (Room A) 15:30~15:50 Treatment-tailored ADL and behavioral change detection ¹é¹ÎÀç(ºÐ´ç¼¿ï´ëÇб³º´¿ø) ±³À°½Ã°£ 04¿ù 20ÀÏ ¹é¹ü±è±¸±â³ä°ü (Room A) 15:50~16:10 Early neuropsychological parallel intervention: Process-based cognitive training on memory ½Å¹Î¿µ(¼¿ï»ó´ã½É¸®´ëÇпø´ëÇб³) ±³À°½Ã°£ 04¿ù 20ÀÏ ¹é¹ü±è±¸±â³ä°ü (Room A) 16:10~16:30 An area of superficial siderosis ÀåÇý¹Î(¼¿ï´ëÇб³º´¿ø) ±³À°½Ã°£ 04¿ù 20ÀÏ ¹é¹ü±è±¸±â³ä°ü (Room A) 16:30~16:50 >4 microhemorrhages ¼»ó¿ø(¼º±Õ°üÀÇ´ë) ±³À°½Ã°£ 04¿ù 20ÀÏ ¹é¹ü±è±¸±â³ä°ü (Room A) 16:50~17:10 Anticoagulants and tPA ÀÓÀ缺(¿ï»êÀÇ´ë) ±³À°½Ã°£ 04¿ù 20ÀÏ ¹é¹ü±è±¸±â³ä°ü (Room B) 14:00~14:12 [±¸¿¬] TDP-43 Oligomers in Neurodegenerative diseases: AD and SD ¾È¼º¼ö(°¡Ãµ´ëÇб³) ±³À°½Ã°£ 04¿ù 20ÀÏ ¹é¹ü±è±¸±â³ä°ü (Room B) 14:12~14:24 [±¸¿¬] Downregulation of Mest facilitate the progression of AD pathophysiology Á¶ÀÍÈÆ(¼¿ï½Ã¸³´ë »ý¸í°úÇаú) ±³À°½Ã°£ 04¿ù 20ÀÏ ¹é¹ü±è±¸±â³ä°ü (Room B) 14:24~14:36 [±¸¿¬] Identification of genetic risk loci and risk prediction for ¥â-amyloid deposition in East Asian population ±èÁØÇ¥(»ï¼º¼¿ïº´¿ø) ±³À°½Ã°£ 04¿ù 20ÀÏ ¹é¹ü±è±¸±â³ä°ü (Room B) 14:36~14:48 [±¸¿¬] Discordance Between Plasma AD Biomarkers and A¥â PET in Memory Clinic: Prevalence and Clinical Consequences À±Áöȯ(»ï¼º¼¿ïº´¿ø) ±³À°½Ã°£ 04¿ù 20ÀÏ ¹é¹ü±è±¸±â³ä°ü (Room B) 14:48~15:00 [±¸¿¬] White Matter Hyperintensities and Cholinergic Degeneration as Lewy Body Disease °¼º¿ì(¼¼ºê¶õ½ºº´¿ø) ÈÞ½Ä 04¿ù 20ÀÏ ¹é¹ü±è±¸±â³ä°ü (Room B) 15:00~15:10 Coffee Break () ±³À°½Ã°£ 04¿ù 20ÀÏ ¹é¹ü±è±¸±â³ä°ü (Room B) 15:10~15:30 Ä¡¸Å°ü¸®ÁÖÄ¡ÀÇ ½Ã¹ü»ç¾÷ ÃÖÈ£Áø(ÇѾçÀÇ´ë) ±³À°½Ã°£ 04¿ù 20ÀÏ ¹é¹ü±è±¸±â³ä°ü (Room B) 15:30~15:50 °æµµÀÎÁöÀå¾Ö ȯÀÚ°ü¸®¸¦ À§ÇÑ Á¤Ã¥ ¹æÇâ ¼Áö¿ø(Áß¾ÓÄ¡¸Å¼¾ÅÍ) ±³À°½Ã°£ 04¿ù 20ÀÏ ¹é¹ü±è±¸±â³ä°ü (Room B) 15:50~16:10 Áö¿ª »çȸ ÀÎÁö°Ç°ÁõÁø Ãß±¸ Á¤Ã¥ ¾ç¿µ¼ø/ÇÏűæ(´ëÇÑÄ¡¸ÅÇÐȸ º¸ÇèÀÌ»ç/º¸°Çº¹ÁöºÎ ³ëÀΰǰ°úÀå) ±³À°½Ã°£ 04¿ù 20ÀÏ ¹é¹ü±è±¸±â³ä°ü (Room B) 16:10~16:30 Global phase3 trial of AR1001 in Early Alzheimer's Diseases: POLARIS-AD Á¤ÀçÁØ(¾Æ¸®¹ÙÀÌ¿À) ±³À°½Ã°£ 04¿ù 20ÀÏ ¹é¹ü±è±¸±â³ä°ü (Room B) 16:30~16:50 KDS2010(Tisolagiline): A novel inhibitor of aberrant GABA production in reactive astrocytes for treatment of neurodegenerative diseases ±è»ó¿í(´º·Î¹ÙÀÌ¿ÀÁ¨) ±³À°½Ã°£ 04¿ù 20ÀÏ ¹é¹ü±è±¸±â³ä°ü (Room B) 16:50~17:10 Double-blind, Placebo-controlled study of the effects of a live biotherapeutic product in preclincal Alzheimer's disease ÃÖ°È£(Àü³²´ëº´¿ø) ±âŸ 04¿ù 20ÀÏ ¹é¹ü±è±¸±â³ä°ü 17:10~17:30 Closing Remarks ¹× ½Ã»ó½Ä ()
|
Tip. ±³À°ÀÏÁ¤Àº ±³À°±â°üÀÇ »çÁ¤¿¡ µû¶ó º¯°æµÉ ¼ö ÀÖÀ¸¹Ç·Î »çÀü¿¡ ¹Ýµå½Ã ±³À°±â°üÀ¸·Î ¹®ÀÇÇÏ¿© È®ÀÎ ¹Ù¶ø´Ï´Ù. |
|
Á¦¸ñ |
Ãßõ¼ö : 0 , Á¶È¸¼ö : 894 , ´ñ±Û¼ö : 0 |
Ãßõ¼ö : 0 , Á¶È¸¼ö : 832 , ´ñ±Û¼ö : 0 |
Ãßõ¼ö : 0 , Á¶È¸¼ö : 1,023 , ´ñ±Û¼ö : 0 |
Ãßõ¼ö : 0 , Á¶È¸¼ö : 748 , ´ñ±Û¼ö : 0 |
Ãßõ¼ö : 0 , Á¶È¸¼ö : 881 , ´ñ±Û¼ö : 0 |